CorticorpNews
Back to US
Expand

Image: Good News Network

Updated

A one-time infusion of CRISPR gene-editing therapy cut dangerous cholesterol by 52% in a first human trial. Patients still showed the benefit 12 months after treatment, and no side effects were reported. The Cleveland Clinic in Ohio reported that its Phase 1 trial found the CRISPR-Cas9 therapy effective and safe. Researchers present the result as an early step toward one-time treatment for heart disease risk.

1 outlet · 1 article · first seen Nov 21, 11:00 AM ET

Every source article

Corroborated by 1 outlet (GDELT)